Literature DB >> 10339603

Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.

T Ohshima1, R Schiffmann, G J Murray, J Kopp, J M Quirk, S Stahl, C C Chan, P Zerfas, J H Tao-Cheng, J M Ward, R O Brady, A B Kulkarni.   

Abstract

Fabry disease is an X-linked metabolic disorder caused by a deficiency of alpha-galactosidase A (alpha-Gal A). The enzyme defect leads to the systemic accumulation of glycosphingolipids with alpha-galactosyl moieties consisting predominantly of globotriaosylceramide (Gb3). In patients with this disorder, glycolipid deposition in endothelial cells leads to renal failure and cardiac and cerebrovascular disease. Recently, we generated alpha-Gal A gene knockout mouse lines and described the phenotype of 10-week-old mice. In the present study, we characterize the progression of the disease with aging and explore the effects of bone marrow transplantation (BMT) on the phenotype. Histopathological analysis of alpha-Gal A -/0 mice revealed subclinical lesions in the Kupffer cells in the liver and macrophages in the skin with no gross lesions in the endothelial cells. Gb3 accumulation and pathological lesions in the affected organs increased with age. Treatment with BMT from the wild-type mice resulted in the clearance of accumulated Gb3 in the liver, spleen, and heart with concomitant elevation of alpha-Gal A activity. These findings suggest that BMT may have a potential role in the management of patients with Fabry disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10339603      PMCID: PMC26897          DOI: 10.1073/pnas.96.11.6423

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

Review 1.  State of the art review. Bone marrow transplantation treatment for storage diseases. Keystone. January 23, 1992.

Authors:  W Krivit; E Shapiro; P M Hoogerbrugge; H W Moser
Journal:  Bone Marrow Transplant       Date:  1992       Impact factor: 5.483

Review 2.  Treatment of genetic defects in hematopoietic cell function by gene transfer.

Authors:  S Karlsson
Journal:  Blood       Date:  1991-11-15       Impact factor: 22.113

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Isolation and relationship of human hexosaminidases.

Authors:  J F Tallman; R O Brady; J M Quirk; M Villalba; A E Gal
Journal:  J Biol Chem       Date:  1974-06-10       Impact factor: 5.157

5.  Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease.

Authors:  R O Brady; J F Tallman; W G Johnson; A E Gal; W R Leahy; J M Quirk; A S Dekaban
Journal:  N Engl J Med       Date:  1973-07-05       Impact factor: 91.245

6.  Analytical separation of nonlipid water soluble substances and gangliosides from other lipids by dextran gel column chromatography.

Authors:  A N Siakotos
Journal:  J Am Oil Chem Soc       Date:  1965-11       Impact factor: 1.849

7.  Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease.

Authors:  J S Mayes; J B Scheerer; R N Sifers; M L Donaldson
Journal:  Clin Chim Acta       Date:  1981-05-05       Impact factor: 3.786

8.  Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes.

Authors:  I Hozumi; M Nishizawa; T Ariga; T Miyatake
Journal:  J Lipid Res       Date:  1990-02       Impact factor: 5.922

9.  Endocytosis of lysosomal alpha-galactosidase A by cultured fibroblasts from patients with Fabry disease.

Authors:  J S Mayes; E L Cray; V A Dell; J B Scheerer; R N Sifers
Journal:  Am J Hum Genet       Date:  1982-07       Impact factor: 11.025

10.  Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives.

Authors:  M D Ullman; R H McCluer
Journal:  J Lipid Res       Date:  1977-05       Impact factor: 5.922

View more
  32 in total

1.  Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors.

Authors:  Makoto Yoshimitsu; Takeya Sato; Kesheng Tao; Jagdeep S Walia; Vanessa I Rasaiah; Gillian T Sleep; Gary J Murray; Armando G Poeppl; John Underwood; Lori West; Roscoe O Brady; Jeffrey A Medin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-18       Impact factor: 11.205

2.  Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice.

Authors:  Hitoshi Sakuraba; Mai Murata-Ohsawa; Ikuo Kawashima; Youichi Tajima; Masaharu Kotani; Toshio Ohshima; Yasunori Chiba; Minako Takashiba; Yoshifumi Jigami; Tomoko Fukushige; Tamotsu Kanzaki; Kohji Itoh
Journal:  J Hum Genet       Date:  2005-12-22       Impact factor: 3.172

Review 3.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

4.  Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice.

Authors:  Natalia Pacienza; Makoto Yoshimitsu; Nobuo Mizue; Bryan C Y Au; James C M Wang; Xin Fan; Toshihiro Takenaka; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-04-03       Impact factor: 11.454

5.  Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys.

Authors:  Takahiro Tsukimura; Ikuo Kawashima; Tadayasu Togawa; Takashi Kodama; Toshihiro Suzuki; Toru Watanabe; Yasunori Chiba; Yoshifumi Jigami; Tomoko Fukushige; Takuro Kanekura; Hitoshi Sakuraba
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

6.  Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.

Authors:  Brandon Durant; Sabrina Forni; Lawrence Sweetman; Nastry Brignol; Xing-Li Meng; Elfrida R Benjamin; Raphael Schiffmann; Jin-Song Shen
Journal:  J Lipid Res       Date:  2011-07-11       Impact factor: 5.922

7.  A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.

Authors:  Atsumi Taguchi; Hiroki Maruyama; Masaaki Nameta; Tadashi Yamamoto; Junichiro Matsuda; Ashok B Kulkarni; Hidekatsu Yoshioka; Satoshi Ishii
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

8.  Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach.

Authors:  David F Moore; Monique P Gelderman; Paulo A Ferreira; Steven R Fuhrmann; Haiqing Yi; Abdel Elkahloun; Lisa M Lix; Roscoe O Brady; Raphael Schiffmann; Ehud Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

9.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 10.  Sphingolipids and membrane biology as determined from genetic models.

Authors:  Raghavendra Pralhada Rao; Jairaj K Acharya
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-10-13       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.